Riociguat — Discount Pricing

Other medications in Heart & Cardiovascular

• Rivaroxaban
• Rosuvastatin
• Sacubitril-Valsartan
• Selexipag
• Sildenafil (PAH)
• Simvastatin
• Sotalol
• Tadalafil (PAH)

What Riociguat is approved for (FDA label)

Adempas is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with: • Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class. ( 1.1 ) • Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and to delay clinical worsening. ( 1.2 ) 1.1 Chronic-Thromboembolic Pulmonary Hypertension Adempas is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class [see Clinical Studies (14.1) ]. 1.2 Pulmonary Arterial Hypertension Adempas is indicated for the treatment of adults with pulmonary arterial hypertension (PAH), (WHO Group 1), to improve exercise capacity, WHO functional class and to delay clinical worsening.

Source: Read the full FDA label on DailyMed. Label effective date: August 13, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Riociguat (FDA label)

WARNING: EMBRYO-FETAL TOXICITY Adempas is contraindicated for use during pregnancy because it may cause fetal harm based on animal data [see Contraindications (4.1) , Warnings and Precautions (5.1) , and Use in Specific Populations (8.1) ]. Exclude pregnancy prior to the start of treatment with Adempas. Advise use of effective contraception prior to initiation of treatment, during treatment, and for one month after treatment with Adempas [see Dosage and Administration (2.3) , Warnings and Precautions (5.1) , and Use in Specific Populations (8.3) ]. If pregnancy is detected, discontinue Adempas as soon as possible [see Warnings and Precautions (5.1) ]. WARNING: EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning Based on animal data, Adempas may cause fetal harm if used during pregnancy. ( 4.1 , 5.1 , 8.1 ) Exclude pregnancy before start of treatment Use effective contraception prior to initiation of treatment, during treatment, and for one month after treatment with Adempas. ( 2.3 , 5.1 , 8.6 ) When pregnancy is detected, discontinue Adempas as soon as possible. ( 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: 7b57509a-3d5d-41d4-8fed-1471e26372a3. SPL document ID: 21ffd9c9-204f-4809-af50-5e6f26e9d4ce. Label effective date: August 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Riociguat (FDA label)

Tablets: film-coated, round, bi-convex: • 0.5 mg, white, with "BAYER" cross on one side and "0.5" and "R" on the other side • 1 mg, pale-yellow, with "BAYER" cross on one side and "1" and "R" on the other side • 1.5 mg, yellow-orange, with "BAYER" cross on one side and "1.5" and "R" on the other side • 2 mg, pale orange, with "BAYER" cross on one side and "2" and "R" on the other side • 2.5 mg, red-orange, with "BAYER" cross on one side and "2.5" and "R" on the other side Tablets: 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 7b57509a-3d5d-41d4-8fed-1471e26372a3. SPL document ID: 21ffd9c9-204f-4809-af50-5e6f26e9d4ce. Label effective date: August 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Riociguat (FDA label)

The following serious adverse reactions are discussed elsewhere in the labeling: • Embryo-Fetal Toxicity [see Warnings and Precautions (5.1) ] • Hypotension [see Warnings and Precautions (5.2) ] • Bleeding [see Warnings and Precautions (5.3) ] Adverse reactions occurring more frequently (≥3%) on Adempas compared to placebo are headache, dyspepsia/gastritis, dizziness, nausea, diarrhea, hypotension, vomiting, anemia, gastroesophageal reflux, and constipation. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-842-2937 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 7b57509a-3d5d-41d4-8fed-1471e26372a3. SPL document ID: 21ffd9c9-204f-4809-af50-5e6f26e9d4ce. Label effective date: August 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Riociguat (FDA label)

• Pregnancy ( 4.1 ) • Use with nitrates or nitric oxide donors in any form ( 4.2 , 7.1 ) • Use with PDE inhibitors ( 2.6 , 4.3 , 7.1 ) • Patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators. ( 4.4 , 7.1 ) • Pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP) ( 4.5 ) 4.1 Pregnancy Use of Adempas is contraindicated in patients who are pregnant [see Warnings and Precautions (5.1) , Use in Specific Populations ( 8.1 )] . 4.2 Nitrates and Nitric Oxide Donors Co-administration of Adempas with nitrates or nitric oxide donors (such as amyl nitrite) in any form is contraindicated [see Drug Interactions (7.1) and Clinical Pharmacology (12.2) ] . 4.3 Phosphodiesterase Inhibitors Concomitant administration of Adempas with specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) or nonspecific PDE-5 inhibitors (such as dipyridamole or theophylline) is contraindicated [see Dosage and Administration (2.6), Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.2 )]. Do not administer within 24 hours of sildenafil.

Source: FDA prescribing information (DailyMed). Set ID: 7b57509a-3d5d-41d4-8fed-1471e26372a3. SPL document ID: 21ffd9c9-204f-4809-af50-5e6f26e9d4ce. Label effective date: August 13, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.